Belite Bio (NASDAQ: BLTE) has recently received a number of price target changes and ratings updates:
- 9/4/2026 – Belite Bio is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $303.00 price target on the stock.
- 9/3/2026 – Belite Bio had its “buy” rating reaffirmed by UBS Group AG.
- 9/3/2026 – Belite Bio had its “buy” rating reaffirmed by HC Wainwright.
- 8/18/2026 – Belite Bio was downgraded by Zacks Research from “strong-buy” to “hold”.
- 8/14/2026 – Belite Bio had its price target raised by Morgan Stanley from $201.00 to $206.00. They now have an “overweight” rating on the stock.
- 8/14/2026 – Belite Bio had its “buy” rating reaffirmed by Benchmark Co..
- 8/14/2026 – Belite Bio was given a new $220.00 price target by Mizuho.
- 8/12/2026 – Belite Bio had its price target raised by Cantor Fitzgerald from $266.00 to $270.00. They now have an “overweight” rating on the stock.
- 8/12/2026 – Belite Bio had its price target raised by HC Wainwright from $200.00 to $214.00. They now have a “buy” rating on the stock.
- 7/22/2026 – Belite Bio had its “buy” rating reaffirmed by HC Wainwright.
- 7/20/2026 – Belite Bio was upgraded by Zacks Research from “hold” to “strong-buy”.
- 7/6/2026 – Belite Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
Insider Buying and Selling at Belite Bio
In other news, insider Hendrik Scholl sold 10,000 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $145.24, for a total value of $1,452,400.00. Following the transaction, the insider owned 15,000 shares of the company’s stock, valued at $2,178,600. This represents a 40.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Yu-Hsin Lin sold 365 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $180.35, for a total value of $65,827.75. Following the completion of the transaction, the chief executive officer owned 170,569 shares in the company, valued at $30,762,119.15. This represents a 0.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 20,732 shares of company stock worth $2,990,116. Insiders own 13.29% of the company’s stock.
Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.
Featured Stories
- Five stocks we like better than Belite Bio
- Defense Stocks Are Pulling Back as Their Navy Tailwinds Get Stronger
- Survey Reveals: America’s Top Autumn Activities that are Free [2026]
- Defying Gravity: Space Stocks Reach Escape Velocity
- Credo Technology Just Plunged 20%—Did the Market Overreact?
Receive News & Ratings for Belite Bio Inc Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio Inc Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
